-5.2%
DASH vs MRNA
+49.3%
-54.5%
-82.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | +5.3% | -5.4% | -0.7% |
| 7D | +0.4% | +14.6% | -14.3% | -1.1% |
| 30D | -6.0% | +29.4% | -35.4% | -9.0% |
| 3M | -15.8% | +371.9% | -387.7% | -38.2% |
| 6M | +7.0% | +421.0% | -414.0% | -24.6% |
| YTD | -20.7% | +762.0% | -782.6% | -51.5% |
| 1Y | -8.5% | +944.8% | -953.3% | -47.1% |
| 3Y | +101.8% | +252.7% | -150.9% | +34.2% |
| 5Y | -9.6% | +7.3% | -16.8% | -19.7% |
| All | -5.2% | +49.3% | -54.5% | -40.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling